News articles about MedEquities Realty Trust (NYSE:MRT) have been trending positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. MedEquities Realty Trust earned a media sentiment score of 0.31 on Accern’s scale. Accern also assigned news headlines about the financial services provider an impact score of 46.4109087208428 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern Sentiment’s analysis:

MedEquities Realty Trust (NYSE:MRT) traded up $0.04 on Friday, hitting $11.74. 156,501 shares of the stock traded hands, compared to its average volume of 174,887. The company has a market cap of $373.03, a P/E ratio of 9.32 and a beta of -0.70. MedEquities Realty Trust has a one year low of $10.28 and a one year high of $13.06.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 29th. Stockholders of record on Wednesday, November 15th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 7.16%. The ex-dividend date is Tuesday, November 14th. MedEquities Realty Trust’s payout ratio is currently 240.00%.

MRT has been the topic of several analyst reports. KeyCorp reaffirmed a “buy” rating and set a $13.00 price target on shares of MedEquities Realty Trust in a research note on Friday, August 25th. Capital One Financial Corporation initiated coverage on shares of MedEquities Realty Trust in a research note on Monday, October 23rd. They set an “equal weight” rating and a $13.00 price target on the stock. Cantor Fitzgerald initiated coverage on shares of MedEquities Realty Trust in a research note on Thursday, August 31st. They set an “overweight” rating and a $14.00 price target on the stock. Finally, Zacks Investment Research raised shares of MedEquities Realty Trust from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $13.00.

TRADEMARK VIOLATION WARNING: “Favorable Media Coverage Somewhat Unlikely to Affect MedEquities Realty Trust (MRT) Share Price” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at

About MedEquities Realty Trust

MedEquities Realty Trust, Inc is a real estate investment trust (REIT). The Company invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company invests primarily in real estate across the acute and post-acute spectrum of care. It focuses on investing in various types of healthcare properties, including acute care hospitals; skilled nursing facilities; short-stay surgical and specialty hospitals, which focus on orthopedic, heart and other dedicated surgeries and specialty procedures; dedicated specialty hospitals, such as inpatient rehabilitation facilities, long-term acute care hospitals and facilities providing psychiatric care; physician clinics; diagnostic facilities; outpatient surgery centers, and facilities that support these services, such as medical office buildings.

Insider Buying and Selling by Quarter for MedEquities Realty Trust (NYSE:MRT)

Receive News & Ratings for MedEquities Realty Trust Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedEquities Realty Trust Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.